A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy
and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination
with ribavirin in participants with CHD.